MassDevice Q&A: Jean-Marc Wismer

July 14, 2009 by Brian Johnson

The CEO of Switzerland's Sensimed looks to peel back the lid on glaucoma testing.

You literally cannot see glaucoma coming.

Although it's one of the leading causes of blindness in the world, frighteningly little is known about a disease group that affects 4 percent of the world's population over the age of 40. No cure is on the horizon. And due to the insidious nature of the disease, which stars gradually affecting sight from the periphery, most people don't even know they're suffering from glaucoma until it's too late.

Swiss diagnostics company Sensimed AG sees this mysterious disease as a real opportunity.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Features

The software flaw that allowed a duo of cybersecurity researchers to bring down a Philips XPER hospital management system with 6 lines of code is still a problem in current XPER machines, Philips tells MassDevice.com.

MassDevice.com discusses Boston Scientific's playbook for China, India, Russia and Brazil with Asia-Pacific president Supratim Bose.

Boston Scientific CFO Jeffrey Capello tells MassDevice.com how the medical device company plans to pull itself out of one of the roughest patches in its history.

Direct Flow Medical and CEO Bernie Lyons are betting that its heart valve technology can use the decade's worth of experience of the medical device industry's transcatheter aortic valve implant pioneers to leapfrog the competition.

Johns Hopkins patient safety expert Peter Pronovost on medical errors, medical device data and the role medtech must accept in preventing needless deaths.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp